MALVERN, Pa.--(BUSINESS WIRE)--DSG, Inc and Sirion Therapeutics collaborated in launching the industry’s first two pivotal Phase 3 studies using entirely electronic source data collection for the safety and efficacy of Difluprednate in the management of inflammation following ocular surgery. Thanks to the novel and innovative methods used during the study, Sirion received FDA approval of Difluprednate. 100% eSource and the fully integrated eCaselink system enabled remote monitoring by Sirion’s
| < Prev | Next > |
|---|
